Menu
Research Access
Research Access

News & Insights

Stay up to date with the latest news, market commentary, and strategic insights from the team at D. Boral Capital.

Our Team
Transactions

News & Insights

Stay up to date with the latest news, market commentary, and strategic insights from the team at D. Boral Capital.

Our Team
Transactions

Featured Insights

October 17, 2025

D. Boral Capital Acted as Exclusive Financial Advisor to OBOOK Holdings Inc. (Nasdaq: OWLS) in Connection with its Direct Listing

Read More

October 17, 2025

D. Boral Capital Acted as Exclusive Placement Agent to Vivakor, Inc. (Nasdaq: VIVK) in Connection with its $5,000,000 Registered Direct Offering

Read More

October 7, 2025

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte, Inc. (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

Read More

October 7, 2025

D. Boral Capital Acted as Sole Bookrunner to GigCapital8 Corp. (Nasdaq: GIW) in Connection with its $253,000,000 Million SPAC Initial Public Offering

Read More

September 29, 2025

D. Boral Capital Acted as Sole Bookrunner to Megan Holdings Limited (Nasdaq: MGN) in Connection with its $5,000,000 Initial Public Offering

Read More

Breakthrough in Neuropsychiatry: Stabilized D-Cycloserine the Future of TMS Augmentation with the CMIO of NRx Pharmaceuticals

Join Jason Kolbert, Head of Research at D. Boral Capital and Prof. Joshua Brown, MD, PhD, CMIO of NRx Pharmaceuticals, to learn more about the clinical relevance of DCS in modern psychiatric care, the implications of improved formulation stability, and how this approach could fit within evolving treatment frameworks that include TMS, ketamine, and other rapid-acting antidepressants. We will also explore the potential for integration with NRx’s expanding clinic model and the broader commercial opportunity in treatment-resistant depression.

REGISTER TODAY

Citius Pharmaceuticals: From Development Stage to Commercial Oncology – A Live Discussion with CEO Leonard Mazur

Review this insightful fireside discussion with Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals, and Jason Kolbert, Head of Research at D. Boral Capital. The conversation explores early LYMPHIR launch traction and physician adoption, alongside the company’s commercial execution strategy in a rare oncology market. The discussion also covers balance sheet positioning, portfolio expansion with Mino-Lok and Halo-Lido, and Citius’ path toward scaling revenue as a multi-asset commercial-stage company.

VIEW WEBINAR

Beyond Air: Commercial Momentum and Global Expansion Driven by LungFit PH

Review this insightful fireside discussion with Steve Lisi, Chief Executive Officer of Beyond Air, Inc. (NASDAQ: XAIR), and Jason Kolbert, Head of Research at D. Boral Capital. The conversation highlights the company’s growing commercial foundation anchored by LungFit PH, including real-world hospital adoption, utilization trends, and the expanding role of nitric oxide delivery as a differentiated respiratory therapy platform.

View Webinar

Advancing Acute Psychiatric Care: Ketamine, Suicide Prevention, and a National Treatment Platform at NRx Pharmaceuticals

Review our in-depth fireside discussion with Jonathan C. Javitt, M.D., M.P.H., Founder, Chairman, Chief Scientist and CEO of NRx Pharmaceuticals, Inc., and Jason Kolbert, Head of Research at D. Boral Capital, focused on NRx’s evolving approach to acute psychiatric care and its strategy to address some of the most urgent unmet needs in mental health.

View Webinar

Reframing Alzheimer’s Drug Development: Clinical Signals, Regulatory Review, and the Path Forward for ANAVEX®2-73

Review our in-depth fireside chat with Anavex Life Sciences Corp. focused on its lead program, ANAVEX®2-73 (blarcamesine), and the evolving scientific and regulatory landscape surrounding early Alzheimer’s disease.

View Webinar

Transforming Critical Care: CytoSorbents’ Blood-Purification Programs Deliver Growing Revenues as DrugSorb-ATR Moves Toward a Mid-2026 FDA Review

This webinar discussion covers CytoSorb commercial momentum, the regulatory path for DrugSorb-ATR, the De Novo submission, and key financial milestones shaping CytoSorbents’ next phase of growth.

View Webinar

A New Wave in Neurodegeneration Treatment: How Clene’s CNS—Gold Nano-Particle Program (CNM-Au8®) Aims to Target Disease Progression in ALS, MS, and PD.

This fireside conversation between D. Boral Capital and Clene Nanomedicine reviews Clene’s CNS—Gold Nano-Particle (CNM-Au8®) program, the science behind targeting bioenergetic failure, and the company’s advancing work in ALS and other neurodegenerative diseases.

View Webinar

Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

This webinar explores recent breakthroughs in treatment approaches for inflammatory disease treatment, focusing on new clinical insights from Enlivex’s knee osteoarthritis program.

View Webinar

Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

This webinar explores recent breakthroughs in treatment approaches, with a focus on new clinical insights from Enlivex’s knee osteoarthritis program.

View Webinar

Recent Transactions

July 10, 2025

Globa Terra Acquisition Corporation

Nasdaq: GTERU

$175,000,000

Initial Public Offering

Sole Bookrunner

Press Release

July 9, 2025

Masonglory Limited

Nasdaq: MSGY

$6,000,000

Initial Public Offering

Sole Bookrunner

Press Release

July 1, 2025

Vendome Acquisition Corporation I

Nasdaq: VNMEU

$200,000,000

Initial Public Offering

Sole Bookrunner

Press Release

June 30, 2025

Veritone, Inc.

Nasdaq: VERI

$10,000,000

Follow-On Offering

Placement Agent

Press Release

June 30, 2025

Yorkville Acquisition Corp.

Nasdaq: YORKU

$172,500,000

Initial Public Offering

Co-Manager

Press Release

June 17, 2025

Brera Holdings PLC

Nasdaq: BREA

$1,400,000

Registered Direct Offering

Exclusive Placement Agent

Press Release

June 11, 2025

Aduro Clean Technologies Inc.

Nasdaq: ADUR

$8,000,000

Follow-On Offering

Sole Bookrunner

Press Release

June 10, 2025

SpaceX Series Interests

SpaceX Series Interests

$4,850,000

Private Placement

Placement Agent

Press Release

June 2, 2025

Medicus Pharma Ltd.

Nasdaq: MDCX

$7,000,000

Follow-On Offering

Co-Placement Agent

Press Release

May 30, 2025

Wintergreen Acquisition Corp.

Nasdaq: WTGUU

$55,950,000

Initial Public Offering

Sole Bookrunner

Press Release
All Transactions
Scroll to Top

John Darwin

Chief Investment Officer

John Darwin is the Chief Investment Officer of D. Boral Capital where he leads the firm’s investment initiatives and portfolio management.

John has 15 years of experience in private equity, venture capital, and corporate development with a focus on high-growth and emerging industries across all geographies. Prior to D. Boral Capital, John was Managing Director of ARC Group where he oversaw the firm’s equity, debt and SPAC investments. Before joining ARC, John held the position of co-founder and Managing Partner of Luminous Capital, a private investment and advisory firm focused on structured credit.

Earlier in his career, John was President of OCG, Inc., a U.S based retail franchisor, where he led the expansion through organic growth and M&A from single location to multi-national operations and eventual sale.

John received his BBA in Finance from Cox School of Business at Southern Methodist University.

Mark Iorio

Head of Equity Capital Markets

Mark Iorio is the Head of Equity Capital Markets at D. Boral Capital.

Since joining the firm in 2022, he has been responsible for managing the placement of more than 200 public and private offerings. Throughout Mark’s career, he has been involved in approximately $20 billion worth of capital raises, ranging from IPOs, Follow-Ons, SPACs, PIPEs, Convertibles, Debt, and Private Placements. Prior to DBC, Mark worked at Maxim Group, where he focused on capital raising initiatives, primarily for private biotechnology, pharmaceutical, and life sciences companies.

Mr. Iorio holds a bachelor’s degree in finance from the Lubin School of Business at Pace University.

Jason Kolbert

Head of Research

Jason Kolbert is the Head of Research at D. Boral Capital. Since joining the firm in 2024, he has worked closely with long-time colleague David Boral to establish and expand the firm’s research platform. Under his leadership, the research team delivers fundamentals-driven analysis through an open-architecture model and actively covers more than 70 companies, with growing coverage across Healthcare, Technology & AI, Industrials, Energy, Financial Services, and Special Situations.

Prior to D. Boral Capital, Jason built a 25-year career as a highly regarded biotechnology analyst and investor. He was most recently Executive Managing Director and Head of Healthcare Research at Maxim Group. Earlier in his career, he spent seven years at Citigroup as a biotechnology analyst and seven years at Susquehanna International Group as a portfolio manager, giving him a unique perspective at the intersection of research and capital markets. Jason began his professional career as a pharmaceutical chemist before moving into international product and marketing management with Schering-Plough in Japan. He later transitioned to Wall Street as a biotechnology research associate at Salomon Smith Barney.

Jason’s research philosophy centers on identifying paradigm-shifting technologies that are disruptive within their industries, supported by rigorous channel checks, valuation metrics, and long-term forecasting—often spanning a decade. In addition to his professional work, he is committed to mentoring the next generation of analysts and fostering integrity in research.

Jason holds a Bachelor of Science in Chemistry from the State University of New York at New Paltz and an MBA from the University of New Haven.

David Lee

Head of Secondaries & Follow-on Investment Banking

David Lee, MBA, is Head of Secondaries & Follow-on Investment Banking at D. Boral Capital. David has spent more than 15+ years in investment banking for capital raising and M&A transactions. Throughout his career, David has advised more than $100B in equity, debt, and M&A transactions for companies across a variety of industries.

David started his IB career at Wachovia and transitioned to Wells Fargo Securities post-merger, and then onto Bank of America Merrill Lynch. After completing his MBA, he resumed his investment banking career at Oppenheimer and then the M&A group at Elevance Health, before joining D. Boral Capital.

David received his MBA from the NYU Stern School of Business.

Ryan J. Whalen

Chief Legal Officer

Ryan J. Whalen has been the Chief Legal Officer of D. Boral Capital since November 2025, previously serving as General Counsel since 2023, and Deputy General Counsel & Head of Litigation since November of 2021.

Prior to joining D. Boral Capital, Ryan spent over two decades as a litigator representing clients faced with complex business disputes. His experience includes handling securities litigation, financial disputes, corporate governance/director and officer litigation, breaches of fiduciary duty, fraud, professional malpractice, employment law, and whistle-blower claims. Ryan also has experience in the Financial Services industry representing investment banks, hedge funds, public companies, and investors. Most recently, Ryan was a Partner at Gusrae Kaplan Nusbaum PLLC. Law, and prior to that, he was a Partner at Brown & Whalen, P.C.

Ryan holds his Juris Doctor degree from Fordham University School of Law and his bachelor’s degree from the University of Rhode Island.

David W. Boral

Chief Executive Officer & Founder

David W. Boral is the Chief Executive Officer and Founder of D. Boral Capital.

Prior to D. Boral Capital, David held several leadership positions in the Investment Banking and Capital Markets industry. His 16 years of expertise spans both public and private transactions, including IPOs, Secondaries/Follow-On Offerings, SPACs, PIPEs, Reverse Mergers, M&A, Bankruptcy/Restructurings, Cross Listings, and other private and public offerings, in the US and abroad. Most recently, David was Co-Head of Investment Banking & Managing Director at Aegis Capital Corp, and prior to that, he was a Director of Investment Banking, at Maxim Group.

In addition to his work at D. Boral Capital, David is dedicated to improving the world around him, specifically the lives of children and veterans. He currently serves on the advisory board for Keep a Child Alive, a nonprofit organization that provides healthcare, housing, and other support services to HIV/AIDS-affected communities in Africa and India. Additionally, David serves on the board for Lifeline Humanitarian Organization, which was founded by Princess Katherine, to reduce and relieve the suffering of physically and mentally disabled children, orphans, and the elderly, as well as to improve medical facilities in Serbia. He also partners with St. Jude Children’s Research Hospital, Heroes Among Us, and Project Rousseau, through corporate sponsorships.

David holds a bachelor’s degree in Business Administration from the Lubin School of Business at Pace University.

Gaurav Verma

Co-Head of Investment Banking

Gaurav Verma has been covering the Technology, Media, and Telecom sector for over 10 years, and has executed over 100 billion in transactions encompassing sell-side and buy-side M&A, IPOs, SPACs, equity offerings, converts, high yield and investment-grade financings. Mr. Verma has advised C-Suite executive teams on M&A assignments, business development opportunities, growth strategies, and capital allocation policies.

Prior to joining D. Boral Capital, Gaurav was a Director at Nomura, spearheading TMT coverage efforts, and previously, was a Senior Vice President at Bank of America Merrill Lynch, within their TMT Investment Banking Group.

Gaurav received his MBA in Finance and Entrepreneurship from the NYU Stern School of Business and BS in Computer Science and Economics from Rutgers University.

Stephanie (Mengjie) Hu

Co-Head of Investment Banking

Stephanie (Mengjie) Hu has been the Head of Asia at D. Boral Capital since May of 2023, previously serving as Vice President, Asia Investment Banking at D. Boral Capital, since November of 2021.

Stephanie has over 9 years of Investment Banking and Financial Services experience. She has completed over 100 transactions across a wide range of industries, representing over $3.5 billion in aggregate value, and has participated in multiple product offerings including IPOs, Follow-Ons/Secondaries, PIPEs, Private Placement, Uplistings (Re-IPO), Reverse Mergers, Registered Directs, CMPOs, ATMs, SPACs and M&As. Her focus is primarily on serving the financial needs of Asian emerging growth and middle-market companies in a variety of industries.

Stephanie holds a Master’s degree in Finance from the University of Rochester, and she is bilingual in English and Mandarin.

Phil Wiederlight

Chief Operating Officer

Phil Wiederlight has been the Chief Operating Officer since November 2023, previously serving as Head of Syndicate, Equity Capital Markets, at D. Boral Capital, since May of 2023.

Phil has spent 15 years in Financial Services, where he has held multiple leadership positions at GoldenTree Asset Management, Sculptor Capital, and JP Morgan. He has completed numerous Capital Markets transactions, which have accounted for several billions of dollars, and has participated in multiple product offerings including IPOs, Follow-Ons/Secondaries, PIPEs, Private Placements, Uplistings (Re-IPO), Reverse Mergers, Registered Directs, CMPOs, ATMs, and SPACs. His experience also includes Cash and Position Reconciliations, Private Equity Structured Products, Trade Settlements, Crypto Settlements, Account Setups, Expense Management, Risk Reporting, and Fund Accounting. Phil has also managed numerous service provider and third-party relationships, which has helped streamline processes and improve internal efficiencies.

Phil holds a Bachelor’s degree in Business Administration from the Miami Herbert Business School at the University of Miami.

Jared S. Merlin

Chief Compliance Officer

Jared S. Merlin has been the Chief Compliance Officer at D. Boral Capital since November of 2022.

Prior to joining D. Boral Capital, Jared spent nine years as a Managing Director at Credit Agricole Corporate and Investment Bank, serving as the Chief Compliance Officer and Head of Capital Markets Compliance. Jared has over two decades of Compliance experience, providing regulatory advice and oversight to investment banks and broker dealers. Prior to Jared’s tenure at Credit Agricole, Jared held various positions in the Compliance Departments of Knight Capital Americas LLC, and Brown Brothers Harriman & Co.

Jared holds a bachelor’s degree from Syracuse University and an MBA from the NYU Stern School of Business.

Ben Reed

Head of Wealth Management

Ben has over a decade of experience in the retail markets, focusing on emerging growth, small, and middle market companies in biotechnology, healthcare, technology, and energy.

Throughout his career, he has helped raise capital for numerous IPOs, secondary offerings, PIPES, and SPACs. He currently holds his series 7, 24, 63, 65, and Insurance Licenses.

He graduated from Villanova University with a Bachelor of Arts degree in Economics and remains an avid Wildcats fan.